SRR1445238
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.521
- INFLAMMATORY_RESPONSE+0.489
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.443
- IL6_JAK_STAT3_SIGNALING+0.430
- KRAS_SIGNALING_DN+0.391
- COAGULATION+0.389
- PANCREAS_BETA_CELLS+0.388
- ALLOGRAFT_REJECTION+0.387
- ANGIOGENESIS+0.356
- KRAS_SIGNALING_UP+0.311
Top 10 suppressed
- DNA_REPAIR-0.494
- PROTEIN_SECRETION-0.468
- OXIDATIVE_PHOSPHORYLATION-0.416
- MITOTIC_SPINDLE-0.355
- NOTCH_SIGNALING-0.324
- MYC_TARGETS_V1-0.296
- WNT_BETA_CATENIN_SIGNALING-0.291
- E2F_TARGETS-0.240
- CHOLESTEROL_HOMEOSTASIS-0.234
- PEROXISOME-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1319539 | GTEX | — | 0.918 |
| 2 | SRR1382869 | GTEX | — | 0.913 |
| 3 | SRR1071289 | GTEX | — | 0.911 |
| 4 | SRR602271 | GTEX | — | 0.909 |
| 5 | SRR1498482 | GTEX | — | 0.908 |
| 6 | SRR1321552 | GTEX | — | 0.907 |
| 7 | SRR1420625 | GTEX | — | 0.906 |
| 8 | SRR1389059 | GTEX | — | 0.905 |
| 9 | SRR1459585 | GTEX | — | 0.903 |
| 10 | SRR1375203 | GTEX | — | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.521 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.489 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.443 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.391 | Remibrutinib | — uncovered |
| COAGULATION | 0.389 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.388 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.387 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.356 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.311 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| COMPLEMENT | 0.253 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| MYOGENESIS | 0.242 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.215 | Inavolisib | — uncovered |
| APOPTOSIS | 0.214 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.212 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.206 | Idelalisib | — uncovered |
| HYPOXIA | 0.183 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.161 | Inavolisib | — uncovered |